U.S. Biosimilars Market Trends, Growth Demand, Opportunities & Forecast To 2027

[Nita Sonwane]

The U.S. biosimilars market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” the U.S. biosimilars market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, the U.S. biosimilars market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.

Browse Summary for this report@ https://www.fortunebusinessinsights.com/industry-reports/u-s-biosim...

some of the key players in the global U.S. biosimilars market:

Hoffmann-La Roche Ltd.
AbbVie Inc.
Merck & Co.
Celltrion Inc.
Coherus BioSciences, Inc.
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
Increased Research and Development Initiatives to Drive the Market

Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.